SCHEMBL1507238

SCHEMBL1507238

O=C1C=C(C(F)F)C(=O)c2ccccc21

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC25B P30305 5/20 0.52
MAPT P10636 4/20 0.52
MAPK1 P28482 4/20 0.52
MEN1 O00255 3/20 0.52
KMT2A Q03164 3/20 0.52
IDO1 P14902 3/20 0.52
CDC25A P30304 3/20 0.52
LMNA P02545 3/20 0.52
SMN1; SMN2 Q16637 3/20 0.52
MAOA P21397 3/20 0.52
ALDH1A1 P00352 3/20 0.52
PLIN1 O60240 2/20 0.52
BLM P54132 2/20 0.52
PLIN5 Q00G26 2/20 0.52
ABHD5 Q8WTS1 2/20 0.52
MAOB P27338 2/20 0.52
SNCA P37840 2/20 0.52
CYP3A4 P08684 2/20 0.52
HPGD P15428 2/20 0.52
NR1I2 O75469 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9627646 0.78 PTPN1 (0.70) CDC25BMAPTMAPK1MEN1KMT2A
SCHEMBL30038980 0.78 PTPN1 (0.70) CDC25BMAPTMAPK1MEN1KMT2A
SCHEMBL5810766 0.78 PTPN1 (0.59) CDC25BMAPTMAPK1MEN1KMT2A
SCHEMBL9628284 0.76 PTPN1 (0.52) CDC25BMAPTMAPK1MEN1KMT2A
SCHEMBL5817375 0.75 PTPN1 (0.55) CDC25BMAPTMAPK1MEN1KMT2A
SCHEMBL7913517 0.75 BACE1 (0.50) CDC25BMAPTMAPK1MEN1KMT2A
Ammonia Solution, Strong SCHEMBL28549609 0.75 PTPN1 (0.50) CDC25BMAPTMAPK1MEN1KMT2A
SCHEMBL28514269 0.74 CDC25B (0.56) CDC25BMAPTMAPK1MEN1KMT2A
SCHEMBL125298 0.73 CDC25B (0.56) CDC25BMAPTMAPK1MEN1KMT2A
SCHEMBL10446585 0.72 PTPN1 (0.47) CDC25BMAPTMAPK1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2257515-B1 1,4-NAPHTHOQUINONE DERIVATIVES AND THERAPEUTIC USE THEREOF CENTRE NAT RECH SCIENT (FR) 2017-05-17 EP disclosed
US-9090549-B2 1,4-naphthoquinones derivatives and therapeutic use thereof CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) 2015-07-28 US disclosed
US-20110059972-A1 1,4-NAPHTHOQUINONES DERIVATIVES AND THERAPEUTIC USE THEREOF CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2011-03-10 US disclosed
EP-2257515-A1 1,4-NAPHTHOQUINONE DERIVATIVES AND THERAPEUTIC USE THEREOF Centre National de la Recherche Scientifique (FR) 2010-12-08 EP disclosed
WO-2009118327-A1 1,4-NAPHTHOQUINONE DERIVATIVES AND THERAPEUTIC USE THEREOF CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2009-10-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110059972-A1 1,4-NAPHTHOQUINONES DERIVATIVES AND THERAPEUTIC USE THEREOF NQO1, NDUFV2, RECQL CDC25B 576/4885MAPT 2505/4885MAPK1 3395/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.